Literature DB >> 21738049

Real-world management of atrial fibrillation in Internal Medicine units: the FADOI 'FALP' observational study.

Mauro Campanini1, Roberto Frediani, Alberto Artom, Giuliano Pinna, Antonella Valerio, Micaela La Regina, Stefania Marengo, Giuliano Lo Pinto, Erica Del Signore, Erminio Bonizzoni, Giovanni Mathieu, Antonino Mazzone, Giorgio Vescovo.   

Abstract

BACKGROUND: Atrial fibrillation is the most frequent arrhythmia, but few data are available on patients' characteristics and management in the context of Internal Medicine wards.
METHODS: Data were collected at the beginning of 2010 in 18 Internal Medicine units of the regions Liguria and Piemonte (Italy). Each centre reviewed the hospital charts of the last 50 patients discharged during the year 2009 in whom a diagnosis of atrial fibrillation had been made (patient's history or during the hospitalization).
RESULTS: A total of 903 atrial fibrillation patients were evaluated. Prevalence of atrial fibrillation among patients hospitalized in Internal Medicine units was 18.2%. More than 85% of patients had at least two diseases other than atrial fibrillation, and 'lone' atrial fibrillation was rare (1.3%). During hospital stay, 80.5% of the patients received at least one treatment for atrial fibrillation: 55.5% received an antithrombotic and 61.8% a drug for arrhythmia, mostly aimed at rate control (47.2%). In-hospital all-cause mortality was 13.4%. At discharge, 70.2 and 68.9% of the patients received prescription of a drug for arrhythmia and for antithrombotic treatment, respectively. Prescription of oral anticoagulants was significantly associated with hypertension, while previous bleeding, age above 75 years, paroxysmal atrial fibrillation, male sex and a number of concomitant drugs of more than four were strong negative predictors.
CONCLUSION: Data from our study confirm that atrial fibrillation is a common finding in patients hospitalized in Internal Medicine units, and this population is characterized by multiple comorbidities and severe prognosis. Discrepancies exist between recommendations by guidelines and real-world management, owing to the complexity of patients and limits of existing treatment strategies.

Entities:  

Mesh:

Year:  2013        PMID: 21738049     DOI: 10.2459/JCM.0b013e328348e5ce

Source DB:  PubMed          Journal:  J Cardiovasc Med (Hagerstown)        ISSN: 1558-2027            Impact factor:   2.160


  2 in total

1.  Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study.

Authors:  Marco Proietti; Alessandro Nobili; Valeria Raparelli; Laura Napoleone; Pier Mannuccio Mannucci; Gregory Y H Lip
Journal:  Clin Res Cardiol       Date:  2016-05-31       Impact factor: 5.460

2.  Handheld ECG Tracking of in-hOspital Atrial Fibrillation The HECTO-AF trial Clinical Study Protocol.

Authors:  Sara Schukraft; Marco Mancinetti; Daniel Hayoz; Yannick Faucherre; Stéphane Cook; Diego Arroyo; Serban Puricel
Journal:  Trials       Date:  2019-01-30       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.